STOCK TITAN

Exicure plans to acquire 20% to 100% of NeuroQ

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Exicure, Inc. (XCUR) entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd. on November 19, 2026, to expand into medical-device technologies for Parkinson’s disease. Exicure intends to acquire a 20% to 100% equity interest in NeuroQ, primarily by issuing Exicure common shares in exchange for NeuroQ shares held by Laonz. The final stake, share-exchange ratio and other terms are to be set in later written agreements, subject to corporate and regulatory approvals and Nasdaq requirements.

After completion of the proposed share acquisition, Exicure intends to provide up to US$500,000 in development funding for X-CUE, subject to applicable approvals, funding availability and definitive funding arrangements. Laonz has completed transfer of X-CUE’s business, including intellectual property, technology, assets and business rights, to NeuroQ. NeuroQ will lead development, clinical evaluation, regulatory approval and commercialization, with strategic support from Exicure. The technology developers say X-CUE’s latest, third-revised device has completed product development and is ready for planned clinical trials; the anticipated evaluation period is approximately six months. Commercialization remains subject to successful clinical evaluation and applicable regulatory approvals.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Planned equity interest in NeuroQ 20% to 100% Range Exicure intends to acquire under the agreement
Planned development funding Up to US$500,000 Intended for X-CUE after completion of the proposed share acquisition, subject to stated conditions
Anticipated clinical evaluation period Approximately six months X-CUE clinical evaluation
X-CUE development history More than a decade Development duration stated for the technology
freezing of gait medical
"Parkinson’s disease who experience freezing of gait"
A brief, episodic inability to start or continue walking despite the intention to do so; the feet feel as if they are glued to the floor and normal stepping is interrupted. It is a symptom commonly seen in movement disorders (most often Parkinsonian syndromes), can be triggered by turning, initiating gait, or navigating narrow spaces, and reflects a disruption in the neural control of walking rather than a problem with the legs themselves.
augmented-reality smart-glasses technology technical
"X-CUE, an augmented-reality smart-glasses technology"
share exchange ratio financial
"the final acquisition percentage, share exchange ratio"
clinical evaluation medical
"ready for planned clinical trials intended to support commercialization"
Clinical evaluation is the systematic review and assessment of medical evidence—such as clinical studies, patient outcomes, and scientific literature—to determine whether a healthcare product is safe and effective for its intended use. For investors, it matters because positive and credible clinical evaluation is like a strong product safety and performance report card: it reduces regulatory risk, increases market credibility, and supports commercial adoption and potential revenue.
intellectual property technical
"including related intellectual property, technology, assets, and business rights"
Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.
regulatory approvals regulatory
"subject to applicable corporate and regulatory approvals"
Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of NeuroQ does Exicure (XCUR) plan to acquire?

Exicure intends to acquire a 20% to 100% equity interest in NeuroQ, primarily through issuing Exicure common shares in exchange for NeuroQ shares held by Laonz. The final percentage, share-exchange ratio and other transaction terms are to be determined in later written agreements, subject to applicable corporate and regulatory approvals and Nasdaq requirements.

How much funding does Exicure (XCUR) plan to provide for X-CUE?

Following completion of the proposed share acquisition, Exicure intends to provide up to US$500,000 in development funding for X-CUE. The funding is subject to applicable approvals, funding availability and definitive funding arrangements.

What is X-CUE’s clinical trial status and expected evaluation period?

The technology developers say X-CUE’s latest, third-revised device has completed product development and is ready for planned clinical trials. The anticipated clinical evaluation period is approximately six months. Potential commercialization remains subject to successful clinical evaluation and applicable regulatory approvals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001698530false00016985302026-11-202026-11-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2026

 

 

Exicure, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39011

81-5333008

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

103 Foulk Road #202

 

Wilmington, Delaware

 

19803

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 847 673-1700

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

XCUR

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 7.01. Regulation FD Disclosure.

On November 20, 2026, Exicure, Inc. (the “Company”) issued a press release announcing that it entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd. on November 19, 2026, in connection with the Company's strategic expansion into medical device technologies designed to assist patients with Parkinson's disease.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.


 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

 

Exhibit Description

99.1

 

Press Release dated November 20, 2026.

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EXICURE, Inc.

 

 

 

 

Date:

20 November 2026

By:

/s/ Jung Soo Kim

 

 

 

Jung Soo Kim
Chief Executive Officer

 


Exhibit 99.1

 

Exicure Announces Strategic Expansion into Parkinson’s Disease

X-CUE Smart Glasses Ready for Clinical Trials Following Over a Decade of Development

img19466653_0.jpg

WILMINGTON, Del., November 20, 2026 – Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 19, 2026, it entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. (“NeuroQ”) and Laonz Co., Ltd. (“Laonz”) to expand its business into medical device technologies designed to assist patients with Parkinson’s disease.

The agreement focuses on X-CUE, an augmented-reality smart-glasses technology developed over more than a decade to assist patients with Parkinson’s disease who experience freezing of gait, a condition that can significantly affect mobility and daily activities.

img19466653_1.jpg

X-CUE augmented-reality smart-glasses technology (product illustration).

X-CUE uses augmented-reality visual cues designed to help patients manage freezing-of-gait episodes and support mobility. According to the technology developers, X-CUE has completed its product development phase for the latest, third-revised version of its medical device and is ready for planned clinical trials intended to support commercialization, with an anticipated clinical evaluation period of approximately six months.

Exicure, Inc. | Press Release | November 20, 2026


Strategic Investment and Business Expansion

Under the agreement, Exicure intends to acquire an equity interest ranging from 20% to 100% in NeuroQ, primarily through the issuance of Exicure common shares in exchange for NeuroQ shares held by Laonz.

The final acquisition percentage, share exchange ratio, and other transaction terms will be determined through subsequent written agreements, subject to applicable corporate and regulatory approvals and Nasdaq requirements.

Following completion of the proposed share acquisition, Exicure intends to provide up to US$500,000 in development funding to support X-CUE’s clinical evaluation, regulatory advancement, manufacturing preparation, and commercialization initiatives, subject to applicable approvals, funding availability, and definitive funding arrangements.

Advancing X-CUE Toward Commercialization

Laonz has completed the transfer of the X-CUE business, including related intellectual property, technology, assets, and business rights, to NeuroQ.

NeuroQ will lead the continued development, clinical evaluation, regulatory approval, and commercialization of X-CUE, with strategic support from Exicure.

The parties intend to leverage the technology’s extensive development history and current product readiness to advance X-CUE through the remaining clinical and regulatory processes toward potential commercialization.

“Through this strategic agreement, we are expanding Exicure’s business into innovative medical device technologies designed to address important unmet needs among patients with Parkinson’s disease,” said Jung Soo Kim, Chief Executive Officer of Exicure. “With more than a decade of development behind X-CUE and the product ready for planned clinical evaluation, we believe this initiative presents a promising opportunity to advance a differentiated technology toward commercialization and create long-term value for our stockholders.”

About X-CUE

X-CUE is an augmented-reality smart-glasses technology designed to assist patients with Parkinson’s disease who experience freezing of gait.

Developed over more than a decade, X-CUE provides visual cues intended to support mobility during freezing-of-gait episodes.

The product has completed its development phase and is being prepared for clinical evaluation, with an anticipated clinical trial period of approximately six months. Potential commercialization remains subject to successful clinical evaluation and applicable regulatory approvals.

About Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) is a biotechnology company focused on advancing innovative healthcare technologies and pursuing strategic growth opportunities.

The Company’s portfolio includes a clinical-stage program targeting stem cell mobilization for multiple myeloma, sickle cell disease, and cell and gene therapy applications.

Exicure is expanding its strategic focus to include medical device technologies designed to address unmet needs in Parkinson’s disease and other healthcare markets.

For more information, visit www.exicuretx.com.

Exicure, Inc. | Press Release | November 20, 2026


Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding the Company’s proposed acquisition of an equity interest in NeuroQ Biologics Inc., the anticipated issuance of Exicure common shares, potential development funding of up to $500,000, the continued development and clinical evaluation of X-CUE technology, the anticipated six-month clinical evaluation period, potential regulatory approvals, and future commercialization opportunities.

Words such as “plans,” “expects,” “will,” “anticipates,” “continue,” “believes,” “may,” “intend,” “could,” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms.

Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results may differ materially due to various factors, including the inability to finalize or complete the proposed acquisition, failure to satisfy applicable closing conditions or obtain required approvals, funding limitations, clinical trial delays or unfavorable results, regulatory uncertainties, and challenges associated with the development and commercialization of X-CUE technology.

For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC.

All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Contact Information

Exicure, Inc.
Investor Relations
Email: pr@exicuretx.com

Exicure, Inc. | Press Release | November 20, 2026


Filing Exhibits & Attachments

2 documents

Keep reading